Sativex® Confirms Clinically Relevant Benefits in Multiple Sclerosis Spasticity

Sativex® Confirms Clinically Relevant Benefits in Multiple Sclerosis Spasticity PR Newswire LYON, France, October 15, 2012 LYON, France, October 15, 2012 /PRNewswire/ -- Positive data from the MObility ImproVEments with Spasticity in Multiple Sclerosis (MOVE) 2 study, presented at ECTRIMS congress, supports the use of Sativex® to reduce symptoms of moderate to severe spasticity due to multiple sclerosis (MSS) The new study data shows that, after three months, 41% of patients treated with Sativex®, who were resistant to other therapies, showed a clinically relevant effect The medicine has proven to be a cost effective treatment in Germany, where Almirall has already made it available as well as in Spain and Denmark Almirall S.A. (ALM) today announces that results of the MObility ImproVEments with Spasticity in Multiple Sclerosis (MOVE) 2 observational study performed in Germany, with 300 patients, showed that one month's treatment with ®Sativex (THC:CBD) oromucosal spray reduces moderate to severe multiple sclerosis spasticity (MSS) by 20% or more in 4 out of 10 patients previously unresponsive to conventional therapies. After three months, the improvement observed was 30% or more. Overall, 55% of the initial patients were eligible for continuing treatment beyond the third month. thThis prospective, observational study was presented on 11th October 2012 at the 28 Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) in Lyon, France.